Multiple Sclerosis Trial, Recruiting (NCT05754593)

Multiple Sclerosis Trial, Recruiting NCT05754593 Sponsor: University Hospital, Bordeaux Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT05754593 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women of childbearing age between 25 and 35 years old
Have been diagnosed with multiple sclerosis (MS) according to a specific set of medical guidelines called the McDonald Criteria 2017
Speak French and have no difficulties understanding information
Are covered by health insurance
Are willing to take part and sign a consent form agreeing to participate

Who may not be able to join:

Have had surgery on their ovaries in the past (such as removal of a cyst or an ovary)
Have a condition called Turner Syndrome (a genetic condition affecting females)
Carry a specific genetic change known as FMR1 premutation, which can affect fertility (confirm with trial site)
Have endometriosis that may have reduced their ovarian reserve (the number of eggs available)
Have previously received chemotherapy or radiation therapy to the pelvic area
Are currently pregnant or breastfeeding
Are persons deprived of liberty, minors, or individuals under a legal protection measure, or anyone unable to give their own consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Valérie BERNARD, MD, University Hospital, Bordeaux

Phone: (0)5 56 79 56 79

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05754593

Sponsor: University Hospital, Bordeaux

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: (0)5 56 79 56 79

More information: https://clinicaltrials.gov/study/NCT05754593

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women of childbearing age between 25 and 35 years old
Have been diagnosed with multiple sclerosis (MS) according to a specific set of medical guidelines called the McDonald Criteria 2017
Speak French and have no difficulties understanding information
Are covered by health insurance
Are willing to take part and sign a consent form agreeing to participate

Who may not be able to join:

Have had surgery on their ovaries in the past (such as removal of a cyst or an ovary)
Have a condition called Turner Syndrome (a genetic condition affecting females)
Carry a specific genetic change known as FMR1 premutation, which can affect fertility (confirm with trial site)
Have endometriosis that may have reduced their ovarian reserve (the number of eggs available)
Have previously received chemotherapy or radiation therapy to the pelvic area
Are currently pregnant or breastfeeding
Are persons deprived of liberty, minors, or individuals under a legal protection measure, or anyone unable to give their own consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Bordeaux

Registry

ClinicalTrials.gov

Start date

4 December 2023

Est. completion

1 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Measure of Anti-Mullerian hormone (AMH) level by blood sample to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov